A Focus on the Link Between Metal Dyshomeostasis, Norepinephrine, and Protein Aggregation
Abstract
:1. Norepinephrine Metabolic Alterations and Their Implication in Neurodegeneration
2. Protein Aggregation: How Metals and Norepinephrine Affect Protein Fibrillation
2.1. NE and Amyloid-β Peptides in AD
2.1.1. Oxidative Modifications Undergone by the Aβ Peptide
2.1.2. NE as a Modulator of Aβ Damage and Aggregation
2.1.3. NE Metabolites Linked to AD
2.2. NE and Tau Protein in AD
2.3. NE and α-Synuclein Protein in PD
3. Metal-Catalyzed Oxidation and Polymerization of NE Leading to Neuromelanic Species
4. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Ross, C.A.; Poirier, M.A. Protein aggregation and neurodegenerative disease. Nat. Med. 2004, 10, S10–S17. [Google Scholar] [CrossRef] [PubMed]
- Pahnke, J.; Langer, O.; Krohn, M. Alzheimer’s and ABC transporters--new opportunities for diagnostics and treatment. Neurobiol. Dis. 2014, 72 Pt A, 54–60. [Google Scholar] [CrossRef]
- Lovell, M.A.; Robertson, J.D.; Teesdale, W.J.; Campbell, J.L.; Markesbery, W.R. Copper, iron and zinc in Alzheimer’s disease senile plaques. J. Neurol. Sci. 1998, 158, 47–52. [Google Scholar] [CrossRef] [PubMed]
- Gaggelli, E.; Kozlowski, H.; Valensin, D.; Valensin, G. Copper homeostasis and neurodegenerative disorders (Alzheimer’s, prion, and Parkinson’s diseases and amyotrophic lateral sclerosis). Chem. Rev. 2006, 106, 1995–2044. [Google Scholar] [CrossRef]
- Zecca, L.; Youdim, M.B.; Riederer, P.; Connor, J.R.; Crichton, R.R. Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 2004, 5, 863–873. [Google Scholar] [CrossRef]
- Dringen, R. Metabolism and functions of glutathione in brain. Prog. Neurobiol. 2000, 62, 649–671. [Google Scholar] [CrossRef]
- Townsend, D.M.; Tew, K.D.; Tapiero, H. The importance of glutathione in human disease. Biomed. Pharmacother. 2003, 57, 145–155. [Google Scholar] [CrossRef]
- Pavlin, M.; Repič, M.; Vianello, R.; Mavri, J. The Chemistry of Neurodegeneration: Kinetic Data and Their Implications. Mol. Neurobiol. 2016, 53, 3400–3415. [Google Scholar] [CrossRef] [PubMed]
- Weydert, C.J.; Cullen, J.J. Measurement of superoxide dismutase, catalase and glutathione peroxidase in cultured cells and tissue. Nat. Protoc. 2010, 5, 51–66. [Google Scholar] [CrossRef]
- Allen, R.G.; Balin, A.K. Oxidative influence on development and differentiation: An overview of a free radical theory of development. Free Radic. Biol. Med. 1989, 6, 631–661. [Google Scholar] [CrossRef]
- Ellwardt, E.; Zipp, F. Molecular mechanisms linking neuroinflammation and neurodegeneration in MS. Exp. Neurol. 2014, 262 Pt A, 8–17. [Google Scholar] [CrossRef]
- Maly, F.E. The B lymphocyte: A newly recognized source of reactive oxygen species with immunoregulatory potential. Free Radic. Res. Commun. 1990, 8, 143–148. [Google Scholar] [CrossRef]
- Hermida-Ameijeiras, A.; Méndez-Alvarez, E.; Sánchez-Iglesias, S.; Sanmartín-Suárez, C.; Soto-Otero, R. Autoxidation and MAO-mediated metabolism of dopamine as a potential cause of oxidative stress: Role of ferrous and ferric ions. Neurochem. Int. 2004, 45, 103–116. [Google Scholar] [CrossRef]
- Matchett, B.J.; Grinberg, L.T.; Theofilas, P.; Murray, M.E. The mechanistic link between selective vulnerability of the locus coeruleus and neurodegeneration in Alzheimer’s disease. Acta Neuropathol. 2021, 141, 631–650. [Google Scholar] [CrossRef]
- Theofilas, P.; Ehrenberg, A.J.; Dunlop, S.; Di Lorenzo Alho, A.T.; Nguy, A.; Leite, R.E.P.; Rodriguez, R.D.; Mejia, M.B.; Suemoto, C.K.; Ferretti-Rebustini, R.E.L.; et al. Locus coeruleus volume and cell population changes during Alzheimer’s disease progression: A stereological study in human postmortem brains with potential implication for early-stage biomarker discovery. Alzheimers Dement. 2017, 13, 236–246. [Google Scholar] [CrossRef] [PubMed]
- Berridge, C.W.; Waterhouse, B.D. The locus coeruleus-noradrenergic system: Modulation of behavioral state and state-dependent cognitive processes. Brain Res. Rev. 2003, 42, 33–84. [Google Scholar] [CrossRef]
- Marien, M.R.; Colpaert, F.C.; Rosenquist, A.C. Noradrenergic mechanisms in neurodegenerative diseases: A theory. Brain Res. Brain Res. Rev. 2004, 45, 38–78. [Google Scholar] [CrossRef] [PubMed]
- Mann, D.M. The locus coeruleus and its possible role in ageing and degenerative disease of the human central nervous system. Mech. Ageing Dev. 1983, 23, 73–94. [Google Scholar] [CrossRef] [PubMed]
- Jinsmaa, Y.; Florang, V.R.; Rees, J.N.; Anderson, D.G.; Strack, S.; Doorn, J.A. Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate. Chem. Res. Toxicol. 2009, 22, 835–841. [Google Scholar] [CrossRef]
- Feng, Q.; Luo, Y.; Zhang, X.N.; Yang, X.F.; Hong, X.Y.; Sun, D.S.; Li, X.C.; Hu, Y.; Li, X.G.; Zhang, J.F.; et al. MAPT/Tau accumulation represses autophagy flux by disrupting IST1-regulated ESCRT-III complex formation: A vicious cycle in Alzheimer neurodegeneration. Autophagy 2020, 16, 641–658. [Google Scholar] [CrossRef]
- Woo, J.A.; Liu, T.; Fang, C.C.; Castaño, M.A.; Kee, T.; Yrigoin, K.; Yan, Y.; Cazzaro, S.; Matlack, J.; Wang, X.; et al. β-Arrestin2 oligomers impair the clearance of pathological tau and increase tau aggregates. Proc. Natl. Acad. Sci. USA 2020, 117, 5006–5015. [Google Scholar] [CrossRef] [PubMed]
- Kang, S.S.; Liu, X.; Ahn, E.H.; Xiang, J.; Manfredsson, F.P.; Yang, X.; Luo, H.R.; Liles, L.C.; Weinshenker, D.; Ye, K. Norepinephrine metabolite DOPEGAL activates AEP and pathological Tau aggregation in locus coeruleus. J. Clin. Investig. 2020, 130, 422–437. [Google Scholar] [CrossRef]
- Matthews, K.L.; Chen, C.P.; Esiri, M.M.; Keene, J.; Minger, S.L.; Francis, P.T. Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Biol. Psychiatry 2002, 51, 407–416. [Google Scholar] [CrossRef]
- Combarros, O.; Warden, D.R.; Hammond, N.; Cortina-Borja, M.; Belbin, O.; Lehmann, M.G.; Wilcock, G.K.; Brown, K.; Kehoe, P.G.; Barber, R.; et al. The dopamine β-hydroxylase -1021C/T polymorphism is associated with the risk of Alzheimer’s disease in the Epistasis Project. BMC Med. Genet. 2010, 11, 162. [Google Scholar] [CrossRef]
- Madrigal, J.L.; Leza, J.C.; Polak, P.; Kalinin, S.; Feinstein, D.L. Astrocyte-derived MCP-1 mediates neuroprotective effects of noradrenaline. J. Neurosci. 2009, 29, 263–267. [Google Scholar] [CrossRef]
- Troadec, J.D.; Marien, M.; Darios, F.; Hartmann, A.; Ruberg, M.; Colpaert, F.; Michel, P.P. Noradrenaline provides long-term protection to dopaminergic neurons by reducing oxidative stress. J. Neurochem. 2001, 79, 200–210. [Google Scholar] [CrossRef]
- Kalinin, S.; Gavrilyuk, V.; Polak, P.E.; Vasser, R.; Zhao, J.; Heneka, M.T.; Feinstein, D.L. Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer’s disease. Neurobiol. Aging 2007, 28, 1206–1214. [Google Scholar] [CrossRef]
- Heneka, M.T.; Nadrigny, F.; Regen, T.; Martinez-Hernandez, A.; Dumitrescu-Ozimek, L.; Terwel, D.; Jardanhazi-Kurutz, D.; Walter, J.; Kirchhoff, F.; Hanisch, U.K.; et al. Locus ceruleus controls Alzheimer’s disease pathology by modulating microglial functions through norepinephrine. Proc. Natl. Acad. Sci. USA 2010, 107, 6058–6063. [Google Scholar] [CrossRef]
- Dello Russo, C.; Boullerne, A.I.; Gavrilyuk, V.; Feinstein, D.L. Inhibition of microglial inflammatory responses by norepinephrine: Effects on nitric oxide and interleukin-1beta production. J. Neuroinflamm. 2004, 1, 9. [Google Scholar] [CrossRef] [PubMed]
- Mercan, D.; Heneka, M.T. The Contribution of the Locus Coeruleus-Noradrenaline System Degeneration during the Progression of Alzheimer’s Disease. Biology 2022, 11, 1822. [Google Scholar] [CrossRef]
- Buettner, G.R. The pecking order of free radicals and antioxidants: Lipid peroxidation, alpha-tocopherol, and ascorbate. Arch. Biochem. Biophys. 1993, 300, 535–543. [Google Scholar] [CrossRef] [PubMed]
- Madrigal, J.L.; Kalinin, S.; Richardson, J.C.; Feinstein, D.L. Neuroprotective actions of noradrenaline: Effects on glutathione synthesis and activation of peroxisome proliferator activated receptor delta. J. Neurochem. 2007, 103, 2092–2101. [Google Scholar] [CrossRef]
- Husain, S.; Hadi, S.M. Strand scission in DNA induced by L-DOPA in the presence of Cu(II). FEBS Lett. 1995, 364, 75–78. [Google Scholar] [CrossRef]
- Linderson, Y.; Baez, S.; Segura-Aguilar, J. The protective effect of superoxide dismutase and catalase against formation of reactive oxygen species during reduction of cyclized norepinephrine ortho-quinone by DT-diaphorase. Biochim. Biophys. Acta 1994, 1200, 197–204. [Google Scholar] [CrossRef]
- Lévay, G.; Ye, Q.; Bodell, W.J. Formation of DNA adducts and oxidative base damage by copper mediated oxidation of dopamine and 6-hydroxydopamine. Exp. Neurol. 1997, 146, 570–574. [Google Scholar] [CrossRef]
- Singh, A.; Das, G.; Kaur, M.; Mallick, B.N. Noradrenaline Acting on Alpha1 Adrenoceptor as well as by Chelating Iron Reduces Oxidative Burden on the Brain: Implications With Rapid Eye Movement Sleep. Front. Mol. Neurosci. 2019, 12, 7. [Google Scholar] [CrossRef]
- Kou, L.; Duan, Y.; Wang, P.; Fu, Y.; Darabedian, N.; He, Y.; Jiang, D.; Chen, D.; Xiang, J.; Liu, G.; et al. Norepinephrine-Fe(III)-ATP Ternary Complex and Its Relevance to Parkinson’s Disease. ACS Chem. Neurosci. 2019, 10, 2777–2785. [Google Scholar] [CrossRef]
- Manini, P.; Panzella, L.; Napolitano, A.; d’Ischia, M. Oxidation chemistry of norepinephrine: Partitioning of the O-quinone between competing cyclization and chain breakdown pathways and their roles in melanin formation. Chem. Res. Toxicol. 2007, 20, 1549–1555. [Google Scholar] [CrossRef]
- Conway, K.A.; Rochet, J.C.; Bieganski, R.M.; Lansbury, P.T. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 2001, 294, 1346–1349. [Google Scholar] [CrossRef]
- Der-Sarkissian, A.; Jao, C.C.; Chen, J.; Langen, R. Structural organization of alpha-synuclein fibrils studied by site-directed spin labeling. J. Biol. Chem. 2003, 278, 37530–37535. [Google Scholar] [CrossRef]
- Fernández, C.O.; Hoyer, W.; Zweckstetter, M.; Jares-Erijman, E.A.; Subramaniam, V.; Griesinger, C.; Jovin, T.M. NMR of alpha-synuclein-polyamine complexes elucidates the mechanism and kinetics of induced aggregation. EMBO J. 2004, 23, 2039–2046. [Google Scholar] [CrossRef]
- Zucca, F.A.; Vanna, R.; Cupaioli, F.A.; Bellei, C.; De Palma, A.; Di Silvestre, D.; Mauri, P.; Grassi, S.; Prinetti, A.; Casella, L.; et al. Neuromelanin organelles are specialized autolysosomes that accumulate undegraded proteins and lipids in aging human brain and are likely involved in Parkinson’s disease. NPJ Park. Dis. 2018, 4, 17. [Google Scholar] [CrossRef]
- Rao, K.S.; Hegde, M.L.; Anitha, S.; Musicco, M.; Zucca, F.A.; Turro, N.J.; Zecca, L. Amyloid beta and neuromelanin--toxic or protective molecules? The cellular context makes the difference. Prog. Neurobiol. 2006, 78, 364–373. [Google Scholar] [CrossRef]
- Halliday, G.M.; Ophof, A.; Broe, M.; Jensen, P.H.; Kettle, E.; Fedorow, H.; Cartwright, M.I.; Griffiths, F.M.; Shepherd, C.E.; Double, K.L. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson’s disease. Brain 2005, 128, 2654–2664. [Google Scholar] [CrossRef]
- Zecca, L.; Zucca, F.A.; Wilms, H.; Sulzer, D. Neuromelanin of the substantia nigra: A neuronal black hole with protective and toxic characteristics. Trends Neurosci. 2003, 26, 578–580. [Google Scholar] [CrossRef]
- Knowles, T.P.; Vendruscolo, M.; Dobson, C.M. The amyloid state and its association with protein misfolding diseases. Nat. Rev. Mol. Cell Biol. 2014, 15, 384–396. [Google Scholar] [CrossRef]
- Westermark, P.; Andersson, A.; Westermark, G.T. Islet Amyloid Polypeptide, Islet Amyloid, and Diabetes Mellitus. Physiol. Rev. 2011, 91, 795–826. [Google Scholar] [CrossRef]
- Chiti, F.; Dobson, C.M. Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade. Annu. Rev. Biochem. 2017, 86, 27–68. [Google Scholar] [CrossRef]
- Trist, B.G.; Hare, D.J.; Double, K.L. Oxidative stress in the aging substantia nigra and the etiology of Parkinson’s disease. Aging Cell 2019, 18, e13031. [Google Scholar] [CrossRef] [PubMed]
- Monzani, E.; Nicolis, S.; Dell’Acqua, S.; Capucciati, A.; Bacchella, C.; Zucca, F.A.; Mosharov, E.V.; Sulzer, D.; Zecca, L.; Casella, L. Dopamine, Oxidative Stress and Protein-Quinone Modifications in Parkinson’s and Other Neurodegenerative Diseases. Angew. Chem. Int. Ed. Engl. 2019, 58, 6512–6527. [Google Scholar] [CrossRef] [PubMed]
- Sulzer, D.; Surmeier, D.J. Neuronal vulnerability, pathogenesis, and Parkinson’s disease. Mov. Disord. 2013, 28, 715–724. [Google Scholar] [CrossRef]
- Giorgi, F.S.; Saccaro, L.F.; Galgani, A.; Busceti, C.L.; Biagioni, F.; Frati, A.; Fornai, F. The role of Locus Coeruleus in neuroinflammation occurring in Alzheimer’s disease. Brain Res. Bull. 2019, 153, 47–58. [Google Scholar] [CrossRef]
- LaFerla, F.M.; Green, K.N.; Oddo, S. Intracellular amyloid-beta in Alzheimer’s disease. Nat. Rev. Neurosci. 2007, 8, 499–509. [Google Scholar] [CrossRef]
- Stancu, I.C.; Vasconcelos, B.; Terwel, D.; Dewachter, I. Models of β-amyloid induced Tau-pathology: The long and “folded” road to understand the mechanism. Mol. Neurodegener. 2014, 9, 51. [Google Scholar] [CrossRef]
- Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science 2002, 297, 353–356. [Google Scholar] [CrossRef]
- Sarell, C.J.; Syme, C.D.; Rigby, S.E.; Viles, J.H. Copper(II) binding to amyloid-beta fibrils of Alzheimer’s disease reveals a picomolar affinity: Stoichiometry and coordination geometry are independent of Abeta oligomeric form. Biochemistry 2009, 48, 4388–4402. [Google Scholar] [CrossRef]
- Danielsson, J.; Pierattelli, R.; Banci, L.; Gräslund, A. High-resolution NMR studies of the zinc-binding site of the Alzheimer’s amyloid beta-peptide. FEBS J. 2007, 274, 46–59. [Google Scholar] [CrossRef]
- Dorlet, P.; Gambarelli, S.; Faller, P.; Hureau, C. Pulse EPR spectroscopy reveals the coordination sphere of copper(II) ions in the 1-16 amyloid-beta peptide: A key role of the first two N-terminus residues. Angew. Chem. Int. Ed. Engl. 2009, 48, 9273–9276. [Google Scholar] [CrossRef]
- Bousejra-ElGarah, F.; Bijani, C.; Coppel, Y.; Faller, P.; Hureau, C. Iron(II) binding to amyloid-β, the Alzheimer’s peptide. Inorg. Chem. 2011, 50, 9024–9030. [Google Scholar] [CrossRef]
- Wallin, C.; Sholts, S.B.; Österlund, N.; Luo, J.; Jarvet, J.; Roos, P.M.; Ilag, L.; Gräslund, A.; Wärmländer, S.K.T.S. Alzheimer’s disease and cigarette smoke components: Effects of nicotine, PAHs, and Cd(II), Cr(III), Pb(II), Pb(IV) ions on amyloid-β peptide aggregation. Sci. Rep. 2017, 7, 14423. [Google Scholar] [CrossRef] [PubMed]
- Wallin, C.; Kulkarni, Y.S.; Abelein, A.; Jarvet, J.; Liao, Q.; Strodel, B.; Olsson, L.; Luo, J.; Abrahams, J.P.; Sholts, S.B.; et al. Characterization of Mn(II) ion binding to the amyloid-β peptide in Alzheimer’s disease. J. Trace Elem. Med. Biol. 2016, 38, 183–193. [Google Scholar] [CrossRef]
- Atwood, C.S.; Perry, G.; Zeng, H.; Kato, Y.; Jones, W.D.; Ling, K.Q.; Huang, X.; Moir, R.D.; Wang, D.; Sayre, L.M.; et al. Copper mediates dityrosine cross-linking of Alzheimer’s amyloid-beta. Biochemistry 2004, 43, 560–568. [Google Scholar] [CrossRef]
- Bin, Y.; Chen, S.; Xiang, J. pH-dependent kinetics of copper ions binding to amyloid-β peptide. J. Inorg. Biochem. 2013, 119, 21–27. [Google Scholar] [CrossRef]
- Cheignon, C.; Tomas, M.; Bonnefont-Rousselot, D.; Faller, P.; Hureau, C.; Collin, F. Oxidative stress and the amyloid beta peptide in Alzheimer’s disease. Redox Biol. 2018, 14, 450–464. [Google Scholar] [CrossRef]
- Smith, D.G.; Cappai, R.; Barnham, K.J. The redox chemistry of the Alzheimer’s disease amyloid beta peptide. Biochim. Biophys. Acta 2007, 1768, 1976–1990. [Google Scholar] [CrossRef]
- Pithadia, A.S.; Lim, M.H. Metal-associated amyloid-β species in Alzheimer’s disease. Curr. Opin. Chem. Biol. 2012, 16, 67–73. [Google Scholar] [CrossRef]
- Falcone, E.; Hureau, C. Redox processes in Cu-binding proteins: The “in-between” states in intrinsically disordered peptides. Chem. Soc. Rev. 2023, 52, 6595–6600. [Google Scholar] [CrossRef]
- Arrigoni, F.; Rizza, F.; Tisi, R.; De Gioia, L.; Zampella, G.; Bertini, L. On the propagation of the OH radical produced by Cu-amyloid beta peptide model complexes. Insight from molecular modelling. Metallomics 2020, 12, 1765–1780. [Google Scholar] [CrossRef]
- Bacchella, C.; Nicolis, S.; Dell’Acqua, S.; Rizzarelli, E.; Monzani, E.; Casella, L. Membrane Binding Strongly Affecting the Dopamine Reactivity Induced by Copper Prion and Copper/Amyloid-β (Aβ) Peptides. A Ternary Copper/Aβ/Prion Peptide Complex Stabilized and Solubilized in Sodium Dodecyl Sulfate Micelles. Inorg. Chem. 2020, 59, 900–912. [Google Scholar] [CrossRef] [PubMed]
- Bacchella, C.; Dell’Acqua, S.; Nicolis, S.; Monzani, E.; Casella, L. A Cu-bis(imidazole) Substrate Intermediate Is the Catalytically Competent Center for Catechol Oxidase Activity of Copper Amyloid-β. Inorg. Chem. 2021, 60, 606–613. [Google Scholar] [CrossRef]
- Bacchella, C.; Dell’Acqua, S.; Nicolis, S.; Monzani, E.; Casella, L. Oxidase Reactivity of Cu. Int. J. Mol. Sci. 2021, 22, 5190. [Google Scholar] [CrossRef]
- Pirota, V.; Dell’Acqua, S.; Monzani, E.; Nicolis, S.; Casella, L. Copper-Aβ Peptides and Oxidation of Catecholic Substrates: Reactivity and Endogenous Peptide Damage. Chemistry 2016, 22, 16964–16973. [Google Scholar] [CrossRef]
- Bacchella, C.; Dell’Acqua, S.; Nicolis, S.; Monzani, E.; Casella, L. The reactivity of copper complexes with neuronal peptides promoted by catecholamines and its impact on neurodegeneration. Coord. Chem. Rev. 2022, 471, 214756. [Google Scholar] [CrossRef]
- Kowalik-Jankowska, T.; Ruta, M.; Wiśniewska, K.; Łankiewicz, L.; Dyba, M. Products of Cu(II)-catalyzed oxidation in the presence of hydrogen peroxide of the 1-10, 1-16 fragments of human and mouse beta-amyloid peptide. J. Inorg. Biochem. 2004, 98, 940–950. [Google Scholar] [CrossRef]
- Inoue, K.; Garner, C.; Ackermann, B.L.; Oe, T.; Blair, I.A. Liquid chromatography/tandem mass spectrometry characterization of oxidized amyloid beta peptides as potential biomarkers of Alzheimer’s disease. Rapid Commun. Mass. Spectrom. 2006, 20, 911–918. [Google Scholar] [CrossRef]
- Schöneich, C. Mechanisms of metal-catalyzed oxidation of histidine to 2-oxo-histidine in peptides and proteins. J. Pharm. Biomed. Anal. 2000, 21, 1093–1097. [Google Scholar] [CrossRef]
- Schöneich, C. Selective Cu2+/ascorbate-dependent oxidation of alzheimer’s disease beta-amyloid peptides. Ann. N. Y. Acad. Sci. 2004, 1012, 164–170. [Google Scholar] [CrossRef]
- Toneff, T.; Funkelstein, L.; Mosier, C.; Abagyan, A.; Ziegler, M.; Hook, V. Beta-amyloid peptides undergo regulated co-secretion with neuropeptide and catecholamine neurotransmitters. Peptides 2013, 46, 126–135. [Google Scholar] [CrossRef]
- Huong, V.T.; Shimanouchi, T.; Shimauchi, N.; Yagi, H.; Umakoshi, H.; Goto, Y.; Kuboi, R. Catechol derivatives inhibit the fibril formation of amyloid-beta peptides. J. Biosci. Bioeng. 2010, 109, 629–634. [Google Scholar] [CrossRef] [PubMed]
- Nam, E.; Derrick, J.S.; Lee, S.; Kang, J.; Han, J.; Lee, S.J.C.; Chung, S.W.; Lim, M.H. Regulatory Activities of Dopamine and Its Derivatives toward Metal-Free and Metal-Induced Amyloid-β Aggregation, Oxidative Stress, and Inflammation in Alzheimer’s Disease. ACS Chem. Neurosci. 2018, 9, 2655–2666. [Google Scholar] [CrossRef] [PubMed]
- Zou, Y.; Qian, Z.; Chen, Y.; Qian, H.; Wei, G.; Zhang, Q. Norepinephrine Inhibits Alzheimer’s Amyloid-β Peptide Aggregation and Destabilizes Amyloid-β Protofibrils: A Molecular Dynamics Simulation Study. ACS Chem. Neurosci. 2019, 10, 1585–1594. [Google Scholar] [CrossRef]
- Qian, Z.; Zhang, Q.; Liu, Y.; Chen, P. Assemblies of amyloid-β30-36 hexamer and its G33V/L34T mutants by replica-exchange molecular dynamics simulation. PLoS ONE 2017, 12, e0188794. [Google Scholar] [CrossRef]
- Gao, D.; Wan, J.; Zou, Y.; Gong, Y.; Dong, X.; Xu, Z.; Tang, J.; Wei, G.; Zhang, Q. The destructive mechanism of Aβ. Phys. Chem. Chem. Phys. 2022, 24, 19827–19836. [Google Scholar] [CrossRef]
- Velander, P.; Wu, L.; Hildreth, S.B.; Vogelaar, N.J.; Mukhopadhyay, B.; Helm, R.F.; Zhang, S.; Xu, B. Catechol-containing compounds are a broad class of protein aggregation inhibitors: Redox state is a key determinant of the inhibitory activities. Pharmacol. Res. 2022, 184, 106409. [Google Scholar] [CrossRef]
- Liu, M.; Wan, L.; Bin, Y.; Xiang, J. Role of norepinephrine in Aβ-related neurotoxicity: Dual interactions with Tyr10 and SNK(26-28) of Aβ. Acta Biochim. Biophys. Sin. 2017, 49, 170–178. [Google Scholar] [CrossRef]
- Tsuzuki, S.; Honda, K.; Uchimaru, T.; Mikami, M.; Tanabe, K. Origin of the Attraction and Directionality of the NH/π Interaction: Comparison with OH/π and CH/π Interactions. J. Am. Chem. Soc. 2000, 122, 11450–11458. [Google Scholar] [CrossRef]
- Pecci, L.; Montefoschi, G.; Cavallini, D. Some new details of the copper-hydrogen peroxide interaction. Biochem. Biophys. Res. Commun. 1997, 235, 264–267. [Google Scholar] [CrossRef]
- Bacchella, C.; Gentili, S.; Bellotti, D.; Quartieri, E.; Draghi, S.; Baratto, M.C.; Remelli, M.; Valensin, D.; Monzani, E.; Nicolis, S.; et al. Binding and Reactivity of Copper to R. Inorg. Chem. 2020, 59, 274–286. [Google Scholar] [CrossRef]
- Dell’Acqua, S.; Bacchella, C.; Monzani, E.; Nicolis, S.; Di Natale, G.; Rizzarelli, E.; Casella, L. Prion Peptides Are Extremely Sensitive to Copper Induced Oxidative Stress. Inorg. Chem. 2017, 56, 11317–11325. [Google Scholar] [CrossRef]
- Butterfield, D.A.; Boyd-Kimball, D. Oxidative Stress, Amyloid-β Peptide, and Altered Key Molecular Pathways in the Pathogenesis and Progression of Alzheimer’s Disease. J. Alzheimers Dis. 2018, 62, 1345–1367. [Google Scholar] [CrossRef]
- Clark, D.L.; Boutros, N.N.; Mendez, M.F. The Brain and Behavior: An Introduction to Behavioral Neuroanatomy, 3rd ed.; Cambridge University Press: Cambridge, UK, 2010. [Google Scholar]
- Morimoto, A.; Irie, K.; Murakami, K.; Masuda, Y.; Ohigashi, H.; Nagao, M.; Fukuda, H.; Shimizu, T.; Shirasawa, T. Analysis of the secondary structure of beta-amyloid (Abeta42) fibrils by systematic proline replacement. J. Biol. Chem. 2004, 279, 52781–52788. [Google Scholar] [CrossRef]
- Sato, M.; Murakami, K.; Uno, M.; Nakagawa, Y.; Katayama, S.; Akagi, K.; Masuda, Y.; Takegoshi, K.; Irie, K. Site-specific inhibitory mechanism for amyloid β42 aggregation by catechol-type flavonoids targeting the Lys residues. J. Biol. Chem. 2013, 288, 23212–23224. [Google Scholar] [CrossRef]
- Enache, T.A.; Oliveira-Brett, A.M. Alzheimer’s disease amyloid beta peptides in vitro electrochemical oxidation. Bioelectrochemistry 2017, 114, 13–23. [Google Scholar] [CrossRef]
- Al-Hilaly, Y.K.; Williams, T.L.; Stewart-Parker, M.; Ford, L.; Skaria, E.; Cole, M.; Bucher, W.G.; Morris, K.L.; Sada, A.A.; Thorpe, J.R.; et al. A central role for dityrosine crosslinking of Amyloid-β in Alzheimer’s disease. Acta Neuropathol. Commun. 2013, 1, 83. [Google Scholar] [CrossRef]
- Hensley, K.; Maidt, M.L.; Yu, Z.; Sang, H.; Markesbery, W.R.; Floyd, R.A. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J. Neurosci. 1998, 18, 8126–8132. [Google Scholar] [CrossRef]
- Vázquez de la Torre, A.; Gay, M.; Vilaprinyó-Pascual, S.; Mazzucato, R.; Serra-Batiste, M.; Vilaseca, M.; Carulla, N. Direct Evidence of the Presence of Cross-Linked Aβ Dimers in the Brains of Alzheimer’s Disease Patients. Anal. Chem. 2018, 90, 4552–4560. [Google Scholar] [CrossRef]
- Yoburn, J.C.; Tian, W.; Brower, J.O.; Nowick, J.S.; Glabe, C.G.; Van Vranken, D.L. Dityrosine cross-linked Abeta peptides: Fibrillar beta-structure in Abeta(1-40) is conducive to formation of dityrosine cross-links but a dityrosine cross-link in Abeta(8-14) does not induce beta-structure. Chem. Res. Toxicol. 2003, 16, 531–535. [Google Scholar] [CrossRef]
- Allnutt, M.A.; Matera, K.M. Stabilization and Reduced Cytotoxicity of Amyloid Beta Aggregates in the Presence of Catechol Neurotransmitters. Neurochem. Res. 2024, 49, 379–387. [Google Scholar] [CrossRef]
- Bolton, J.L.; Dunlap, T. Formation and Biological Targets of Quinones: Cytotoxic versus Cytoprotective Effects. Chem. Res. Toxicol. 2017, 30, 13–37. [Google Scholar] [CrossRef] [PubMed]
- Santa-María, I.; Hernández, F.; Martín, C.P.; Avila, J.; Moreno, F.J. Quinones facilitate the self-assembly of the phosphorylated tubulin binding region of tau into fibrillar polymers. Biochemistry 2004, 43, 2888–2897. [Google Scholar] [CrossRef] [PubMed]
- Napolitano, A.; Manini, P.; d’Ischia, M. Oxidation chemistry of catecholamines and neuronal degeneration: An update. Curr. Med. Chem. 2011, 18, 1832–1845. [Google Scholar] [CrossRef]
- Zhang, Z.; Song, M.; Liu, X.; Su Kang, S.; Duong, D.M.; Seyfried, N.T.; Cao, X.; Cheng, L.; Sun, Y.E.; Ping Yu, S.; et al. Delta-secretase cleaves amyloid precursor protein and regulates the pathogenesis in Alzheimer’s disease. Nat. Commun. 2015, 6, 8762. [Google Scholar] [CrossRef]
- Zhang, Z.; Kang, S.S.; Liu, X.; Ahn, E.H.; He, L.; Iuvone, P.M.; Duong, D.M.; Seyfried, N.T.; Benskey, M.J.; Manfredsson, F.P.; et al. Asparagine endopeptidase cleaves α-synuclein and mediates pathologic activities in Parkinson’s disease. Nat. Struct. Mol. Biol. 2017, 24, 632–642. [Google Scholar] [CrossRef]
- Burke, W.J.; Li, S.W.; Schmitt, C.A.; Xia, P.; Chung, H.D.; Gillespie, K.N. Accumulation of 3,4-dihydroxyphenylglycolaldehyde, the neurotoxic monoamine oxidase A metabolite of norepinephrine, in locus ceruleus cell bodies in Alzheimer’s disease: Mechanism of neuron death. Brain Res. 1999, 816, 633–637. [Google Scholar] [CrossRef]
- Burke, W.J.; Kristal, B.S.; Yu, B.P.; Li, S.W.; Lin, T.S. Norepinephrine transmitter metabolite generates free radicals and activates mitochondrial permeability transition: A mechanism for DOPEGAL-induced apoptosis. Brain Res. 1998, 787, 328–332. [Google Scholar] [CrossRef]
- Zhang, K.; Zhu, Y.; Fenik, P.; Fleysh, D.; Ly, C.; Thomas, S.A.; Veasey, S. Norepinephrine Drives Sleep Fragmentation Activation of Asparagine Endopeptidase, Locus Ceruleus Degeneration, and Hippocampal Amyloid-β. J. Neurosci. 2024, 44, e1929232024. [Google Scholar] [CrossRef]
- Antón-Fernández, A.; Vallés-Saiz, L.; Avila, J.; Hernández, F. Neuronal nuclear tau and neurodegeneration. Neuroscience 2023, 518, 178–184. [Google Scholar] [CrossRef]
- Kang, S.S.; Meng, L.; Zhang, X.; Wu, Z.; Mancieri, A.; Xie, B.; Liu, X.; Weinshenker, D.; Peng, J.; Zhang, Z.; et al. Tau modification by the norepinephrine metabolite DOPEGAL stimulates its pathology and propagation. Nat. Struct. Mol. Biol. 2022, 29, 292–305. [Google Scholar] [CrossRef]
- Yang, J.; Zhi, W.; Wang, L. Role of Tau Protein in Neurodegenerative Diseases and Development of Its Targeted Drugs: A Literature Review. Molecules 2024, 29, 2812. [Google Scholar] [CrossRef]
- Bacchella, C.; Guerriere, T.B.; Monzani, E.; Dell’Acqua, S. Cysteine in the R3 Tau Peptide Modulates Hemin Binding and Reactivity. Inorg. Chem. 2024, 63, 11986–12002. [Google Scholar] [CrossRef]
- Bacchella, C.; Gentili, S.; Mozzi, S.I.; Monzani, E.; Casella, L.; Tegoni, M.; Dell’Acqua, S. Role of the Cysteine in R3 Tau Peptide in Copper Binding and Reactivity. Int. J. Mol. Sci. 2022, 23, 10726. [Google Scholar] [CrossRef]
- Soeda, Y.; Yoshikawa, M.; Almeida, O.F.; Sumioka, A.; Maeda, S.; Osada, H.; Kondoh, Y.; Saito, A.; Miyasaka, T.; Kimura, T.; et al. Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups. Nat. Commun. 2015, 6, 10216. [Google Scholar] [CrossRef]
- Cheng, S.Y.; Cao, Y.; Rouzbehani, M.; Cheng, K.H. Coarse-grained MD simulations reveal beta-amyloid fibrils of various sizes bind to interfacial liquid-ordered and liquid-disordered regions in phase separated lipid rafts with diverse membrane-bound conformational states. Biophys. Chem. 2020, 260, 106355. [Google Scholar] [CrossRef]
- Wan, J.; Gong, Y.; Xu, Z.; Dong, X.; Wei, G.; Zhang, Q. Molecular dynamics simulations reveal the destabilization mechanism of Alzheimer’s disease-related tau R3-R4 Protofilament by norepinephrine. Biophys. Chem. 2021, 271, 106541. [Google Scholar] [CrossRef]
- Surguchov, A.; Surgucheva, I.; Solessio, E.; Baehr, W. Synoretin--A new protein belonging to the synuclein family. Mol. Cell Neurosci. 1999, 13, 95–103. [Google Scholar] [CrossRef]
- Maroteaux, L.; Campanelli, J.T.; Scheller, R.H. Synuclein: A neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 1988, 8, 2804–2815. [Google Scholar] [CrossRef]
- Stefanis, L. α-Synuclein in Parkinson’s disease. Cold Spring Harb. Perspect. Med. 2012, 2, a009399. [Google Scholar] [CrossRef]
- Sidhu, A.; Wersinger, C.; Moussa, C.E.; Vernier, P. The role of alpha-synuclein in both neuroprotection and neurodegeneration. Ann. N. Y. Acad. Sci. 2004, 1035, 250–270. [Google Scholar] [CrossRef]
- Yavich, L.; Tanila, H.; Vepsäläinen, S.; Jäkälä, P. Role of alpha-synuclein in presynaptic dopamine recruitment. J. Neurosci. 2004, 24, 11165–11170. [Google Scholar] [CrossRef]
- González, N.; Arcos-López, T.; König, A.; Quintanar, L.; Menacho Márquez, M.; Outeiro, T.F.; Fernández, C.O. Effects of alpha-synuclein post-translational modifications on metal binding. J. Neurochem. 2019, 150, 507–521. [Google Scholar] [CrossRef]
- Paik, H.Y.; Joung, H.; Lee, J.Y.; Lee, H.K.; King, J.C.; Keen, C.L. Serum extracellular superoxide dismutase activity as an indicator of zinc status in humans. Biol. Trace Elem. Res. 1999, 69, 45–57. [Google Scholar] [CrossRef]
- Uversky, V.N.; Li, J.; Fink, A.L. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson’s disease and heavy metal exposure. J. Biol. Chem. 2001, 276, 44284–44296. [Google Scholar] [CrossRef]
- Garza-Lombó, C.; Posadas, Y.; Quintanar, L.; Gonsebatt, M.E.; Franco, R. Neurotoxicity Linked to Dysfunctional Metal Ion Homeostasis and Xenobiotic Metal Exposure: Redox Signaling and Oxidative Stress. Antioxid. Redox Signal 2018, 28, 1669–1703. [Google Scholar] [CrossRef]
- Santner, A.; Uversky, V.N. Metalloproteomics and metal toxicology of α-synuclein. Metallomics 2010, 2, 378–392. [Google Scholar] [CrossRef]
- Binolfi, A.; Theillet, F.X.; Selenko, P. Bacterial in-cell NMR of human α-synuclein: A disordered monomer by nature? Biochem. Soc. Trans. 2012, 40, 950–954. [Google Scholar] [CrossRef]
- Li, J.; Zhu, M.; Manning-Bog, A.B.; Di Monte, D.A.; Fink, A.L. Dopamine and L-dopa disaggregate amyloid fibrils: Implications for Parkinson’s and Alzheimer’s disease. FASEB J. 2004, 18, 962–964. [Google Scholar] [CrossRef]
- Herrera, F.E.; Chesi, A.; Paleologou, K.E.; Schmid, A.; Munoz, A.; Vendruscolo, M.; Gustincich, S.; Lashuel, H.A.; Carloni, P. Inhibition of alpha-synuclein fibrillization by dopamine is mediated by interactions with five C-terminal residues and with E83 in the NAC region. PLoS ONE 2008, 3, e3394. [Google Scholar] [CrossRef]
- Latawiec, D.; Herrera, F.; Bek, A.; Losasso, V.; Candotti, M.; Benetti, F.; Carlino, E.; Kranjc, A.; Lazzarino, M.; Gustincich, S.; et al. Modulation of alpha-synuclein aggregation by dopamine analogs. PLoS ONE 2010, 5, e9234. [Google Scholar] [CrossRef] [PubMed]
- Fischer, A.F.; Matera, K.M. Stabilization of Alpha-Synuclein Oligomers In Vitro by the Neurotransmitters, Dopamine and Norepinephrine: The Effect of Oxidized Catecholamines. Neurochem. Res. 2015, 40, 1341–1349. [Google Scholar] [CrossRef]
- Dibenedetto, D.; Rossetti, G.; Caliandro, R.; Carloni, P. A molecular dynamics simulation-based interpretation of nuclear magnetic resonance multidimensional heteronuclear spectra of α-synuclein·dopamine adducts. Biochemistry 2013, 52, 6672–6683. [Google Scholar] [CrossRef]
- Graham, D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 1978, 14, 633–643. [Google Scholar] [CrossRef]
- Singh, P.; Bhat, R. Binding of Noradrenaline to Native and Intermediate States during the Fibrillation of α-Synuclein Leads to the Formation of Stable and Structured Cytotoxic Species. ACS Chem. Neurosci. 2019, 10, 2741–2755. [Google Scholar] [CrossRef]
- Zou, Y.; Qian, Z.; Gong, Y.; Tang, Y.; Wei, G.; Zhang, Q. Critical nucleus of Greek-key-like core of α-synuclein protofibril and its disruption by dopamine and norepinephrine. Phys. Chem. Chem. Phys. 2019, 22, 203–211. [Google Scholar] [CrossRef]
- Morris, A.M.; Watzky, M.A.; Finke, R.G. Protein aggregation kinetics, mechanism, and curve-fitting: A review of the literature. Biochim. Biophys. Acta 2009, 1794, 375–397. [Google Scholar] [CrossRef]
- Ferrone, F. Analysis of protein aggregation kinetics. Methods Enzymol. 1999, 309, 256–274. [Google Scholar] [CrossRef]
- Kang, S.S.; Ahn, E.H.; Zhang, Z.; Liu, X.; Manfredsson, F.P.; Sandoval, I.M.; Dhakal, S.; Iuvone, P.M.; Cao, X.; Ye, K. α-Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson’s disease. EMBO J. 2018, 37, e98878. [Google Scholar] [CrossRef]
- Mather, M.; Harley, C.W. The Locus Coeruleus: Essential for Maintaining Cognitive Function and the Aging Brain. Trends Cogn. Sci. 2016, 20, 214–226. [Google Scholar] [CrossRef]
- Herbison, A.E.; Simonian, S.X.; Thanky, N.R.; Bicknell, R.J. Oestrogen modulation of noradrenaline neurotransmission. Novartis Found. Symp. 2000, 230, 74–85; discussion 85–93. [Google Scholar] [CrossRef]
- Halliday, G.M.; Leverenz, J.B.; Schneider, J.S.; Adler, C.H. The neurobiological basis of cognitive impairment in Parkinson’s disease. Mov. Disord. 2014, 29, 634–650. [Google Scholar] [CrossRef]
- Zarow, C.; Lyness, S.A.; Mortimer, J.A.; Chui, H.C. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol. 2003, 60, 337–341. [Google Scholar] [CrossRef]
- Betts, M.J.; Kirilina, E.; Otaduy, M.C.G.; Ivanov, D.; Acosta-Cabronero, J.; Callaghan, M.F.; Lambert, C.; Cardenas-Blanco, A.; Pine, K.; Passamonti, L.; et al. Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. Brain 2019, 142, 2558–2571. [Google Scholar] [CrossRef] [PubMed]
- Zecca, L.; Bellei, C.; Costi, P.; Albertini, A.; Monzani, E.; Casella, L.; Gallorini, M.; Bergamaschi, L.; Moscatelli, A.; Turro, N.J.; et al. New melanic pigments in the human brain that accumulate in aging and block environmental toxic metals. Proc. Natl. Acad. Sci. USA 2008, 105, 17567–17572. [Google Scholar] [CrossRef] [PubMed]
- Meredith, P.; Sarna, T. The physical and chemical properties of eumelanin. Pigment. Cell Res. 2006, 19, 572–594. [Google Scholar] [CrossRef]
- Zecca, L.; Costi, P.; Mecacci, C.; Ito, S.; Terreni, M.; Sonnino, S. Interaction of human substantia nigra neuromelanin with lipids and peptides. J. Neurochem. 2000, 74, 1758–1765. [Google Scholar] [CrossRef]
- Engelen, M.; Vanna, R.; Bellei, C.; Zucca, F.A.; Wakamatsu, K.; Monzani, E.; Ito, S.; Casella, L.; Zecca, L. Neuromelanins of human brain have soluble and insoluble components with dolichols attached to the melanic structure. PLoS ONE 2012, 7, e48490. [Google Scholar] [CrossRef]
- Zucca, F.A.; Capucciati, A.; Bellei, C.; Sarna, M.; Sarna, T.; Monzani, E.; Casella, L.; Zecca, L. Neuromelanins in brain aging and Parkinson’s disease: Synthesis, structure, neuroinflammatory, and neurodegenerative role. IUBMB Life 2023, 75, 55–65. [Google Scholar] [CrossRef]
- Capucciati, A.; Zucca, F.A.; Monzani, E.; Zecca, L.; Casella, L.; Hofer, T. Interaction of Neuromelanin with Xenobiotics and Consequences for Neurodegeneration; Promising Experimental Models. Antioxidants 2021, 10, 824. [Google Scholar] [CrossRef] [PubMed]
- Enochs, W.S.; Sarna, T.; Zecca, L.; Riley, P.A.; Swartz, H.M. The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson’s disease: A hypothesis. J. Neural Transm. Park. Dis. Dement. Sect. 1994, 7, 83–100. [Google Scholar] [CrossRef] [PubMed]
- Ferrari, E.; Capucciati, A.; Prada, I.; Zucca, F.A.; D’Arrigo, G.; Pontiroli, D.; Bridelli, M.G.; Sturini, M.; Bubacco, L.; Monzani, E.; et al. Synthesis, Structure Characterization, and Evaluation in Microglia Cultures of Neuromelanin Analogues Suitable for Modeling Parkinson’s Disease. ACS Chem. Neurosci. 2017, 8, 501–512. [Google Scholar] [CrossRef]
- Capucciati, A.; Monzani, E.; Sturini, M.; Nicolis, S.; Zucca, F.A.; Bubacco, L.; Bortolus, M.; Zecca, L.; Casella, L. Water-Soluble Melanin-Protein-Fe/Cu Conjugates Derived from Norepinephrine as Reliable Models for Neuromelanin of Human Brain Locus Coeruleus. Angew. Chem. Int. Ed. Engl. 2022, 61, e202204787. [Google Scholar] [CrossRef]
- Ferrari, E.; Engelen, M.; Monzani, E.; Sturini, M.; Girotto, S.; Bubacco, L.; Zecca, L.; Casella, L. Synthesis and structural characterization of soluble neuromelanin analogs provides important clues to its biosynthesis. J. Biol. Inorg. Chem. 2013, 18, 81–93. [Google Scholar] [CrossRef] [PubMed]
- Sivakumar, P.; Nagashanmugam, K.B.; Priyatharshni, S.; Lavanya, R.; Prabhu, N.; Ponnusamy, S. Review on the interactions between dopamine metabolites and α-Synuclein in causing Parkinson’s disease. Neurochem. Int. 2023, 162, 105461. [Google Scholar] [CrossRef]
- Jouanne, M.; Rault, S.; Voisin-Chiret, A.S. Tau protein aggregation in Alzheimer’s disease: An attractive target for the development of novel therapeutic agents. Eur. J. Med. Chem. 2017, 139, 153–167. [Google Scholar] [CrossRef] [PubMed]
- Murray, K.A.; Hu, C.J.; Griner, S.L.; Pan, H.; Bowler, J.T.; Abskharon, R.; Rosenberg, G.M.; Cheng, X.; Seidler, P.M.; Eisenberg, D.S. De novo designed protein inhibitors of amyloid aggregation and seeding. Proc. Natl. Acad. Sci. USA 2022, 119, e2206240119. [Google Scholar] [CrossRef]
- Ashrafian, H.; Zadeh, E.H.; Khan, R.H. Review on Alzheimer’s disease: Inhibition of amyloid beta and tau tangle formation. Int. J. Biol. Macromol. 2021, 167, 382–394. [Google Scholar] [CrossRef] [PubMed]
- Horne, R.I.; Andrzejewska, E.A.; Alam, P.; Brotzakis, Z.F.; Srivastava, A.; Aubert, A.; Nowinska, M.; Gregory, R.C.; Staats, R.; Possenti, A.; et al. Discovery of potent inhibitors of α-synuclein aggregation using structure-based iterative learning. Nat. Chem. Biol. 2024, 20, 634–645. [Google Scholar] [CrossRef]
- Chaudhari, V.; Bagwe-Parab, S.; Buttar, H.S.; Gupta, S.; Vora, A.; Kaur, G. Challenges and Opportunities of Metal Chelation Therapy in Trace Metals Overload-Induced Alzheimer’s Disease. Neurotox. Res. 2023, 41, 270–287. [Google Scholar] [CrossRef]
- Thakur, R.; Karwasra, R.; Umar, T. Understanding Alzheimer’s Disease and its Metal Chelation Therapeutics: A Narrative Review. Curr. Pharm. Des. 2023, 29, 2377–2386. [Google Scholar] [CrossRef]
- Aaseth, J.O.; Nurchi, V.M. Chelation Combination-A Strategy to Mitigate the Neurotoxicity of Manganese, Iron, and Copper? Biomolecules 2022, 12, 1713. [Google Scholar] [CrossRef]
- Zecca, L.; Wilms, H.; Geick, S.; Claasen, J.H.; Brandenburg, L.O.; Holzknecht, C.; Panizza, M.L.; Zucca, F.A.; Deuschl, G.; Sievers, J.; et al. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: Implications for Parkinson’s disease. Acta Neuropathol. 2008, 116, 47–55. [Google Scholar] [CrossRef]
- Zhang, W.; Phillips, K.; Wielgus, A.R.; Liu, J.; Albertini, A.; Zucca, F.A.; Faust, R.; Qian, S.Y.; Miller, D.S.; Chignell, C.F.; et al. Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: Implications for progression of Parkinson’s disease. Neurotox. Res. 2011, 19, 63–72. [Google Scholar] [CrossRef] [PubMed]
- Zhang, W.; Zecca, L.; Wilson, B.; Ren, H.W.; Wang, Y.J.; Wang, X.M.; Hong, J.S. Human neuromelanin: An endogenous microglial activator for dopaminergic neuron death. Front. Biosci. Elite Ed. 2013, 5, 1–11. [Google Scholar] [CrossRef] [PubMed]
(i) Oxidation of histidine residue | (ii) Oxidation of methionine residue |
(iii) Oxidation of phenilalanine residue | (iv) Oxidation of lysine residue |
(v) Oxidation of tyrosine residue | |
(vi) Oxidation of tryptophan residue | (vii) Oxidation of cysteine residue |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bacchella, C.; Capucciati, A.; Monzani, E. A Focus on the Link Between Metal Dyshomeostasis, Norepinephrine, and Protein Aggregation. Antioxidants 2025, 14, 347. https://doi.org/10.3390/antiox14030347
Bacchella C, Capucciati A, Monzani E. A Focus on the Link Between Metal Dyshomeostasis, Norepinephrine, and Protein Aggregation. Antioxidants. 2025; 14(3):347. https://doi.org/10.3390/antiox14030347
Chicago/Turabian StyleBacchella, Chiara, Andrea Capucciati, and Enrico Monzani. 2025. "A Focus on the Link Between Metal Dyshomeostasis, Norepinephrine, and Protein Aggregation" Antioxidants 14, no. 3: 347. https://doi.org/10.3390/antiox14030347
APA StyleBacchella, C., Capucciati, A., & Monzani, E. (2025). A Focus on the Link Between Metal Dyshomeostasis, Norepinephrine, and Protein Aggregation. Antioxidants, 14(3), 347. https://doi.org/10.3390/antiox14030347